BioStock: Lipum advances to phase II with capital raise, moves production to Sweden

Report this content

On leap day, Lipum published the year-end report for 2023, where CEO Ola Sandborgh describes the progress as a “flying start to an exciting journey.” On the same day, Lipum announced a rights issue of SEK 187 million to advance SOL-116 into phase II. In addition, the company has decided to relocate its contract manufacturing of SOL-116 back to Sweden through an agreement with NorthX Biologics. Ola Sandborgh elaborates on the latest news in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/lipum-advances-to-phase-ii-with-capital-raise-moves-production-to-sweden/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se

Subscribe

Documents & Links

Quick facts

BioStock: Lipum advances to phase II with capital raise, moves production to Sweden
Tweet this